Mutant proteases and uses thereof

Abstract

To provide a polypeptide that has glycine-glycine bond breaking activity and has improved bactericidal activity, and a method for using the same.SOLUTION: A polypeptide includes a modification of a specific amino acid residue in a specific amino acid sequence, or an amino acid sequence at least 80% identical to the same, and has glycine-glycine bond breaking activity.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a mutant protease and its use. [Background technology]

[0002] Staphylococcus aureus is one of the most important pathogens for humans and animals, and causes a wide range of diseases, such as skin and eye infections, food poisoning, pneumonia, meningitis, endocarditis, and osteomyelitis. In addition, the emergence of drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), and their nosocomial infections have become serious issues. Therefore, enzymes that can kill Staphylococcus aureus by bacteriolysis are expected to be used in clinical, veterinary, and food engineering applications (Non-Patent Document 1).

[0003] The most widely used bacteriolytic enzyme in industry is lysozyme. However, although lysozyme has a relatively wide range of bacterial cell wall decomposition activity, Staphylococcus aureus is known to be resistant to lysozyme due to its cell wall structure (Non-Patent Document 2).

[0004] On the other hand, the M23 family of proteases is a protease family defined in the MEROPS database as a protease capable of degrading glycine-glycine bonds in peptide sequences, and is known as a bacteriolytic enzyme that has activity in degrading proteoglycans in elastin and bacterial cell walls. Among them, β-lytic metallopeptidase (BLP) belonging to the M23A subfamily has been reported to have strong bacteriolytic activity against gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilis (Non-Patent Documents 3 and 4).

[0005] Heterologous expression of M23A subfamily proteases has been difficult due to the barrier of processing from proproteins to mature proteins, but it has recently been found that by introducing an M23A family protease gene into a Bacillus host and culturing it, it is possible to efficiently produce the mature protein from the culture (Patent Document 1). However, no functional improvement by introducing a mutation into the M23A subfamily protease has been reported so far. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] International Publication No. 2019 / 142773 [Non-patent literature]

[0007] [Non-Patent Document 1] Szweda, Piotr et al. Applied Microbiology and Biotechnology, 2012, 96(5): 1157-1174 [Non-Patent Document 2] Bera, Agnieszka et al. Journal of Bacteriology, 2007, 189(1): 280-283 [Non-Patent Document 3] Li, Shaoliang et al, The Journal of Biochemistry, 1998, 124(2): 332-339 [Non-Patent Document 4] Ahmed, Kashfia et al. Journal of Bioscience and Bioengineering, 2003, 95(1): 27-34 Summary of the Invention [Problem to be solved by the invention]

[0008] The present invention relates to providing a polypeptide which has glycine-glycine bond cleavage activity and improved bactericidal activity, and a method for using the same. [Means for solving the problem]

[0009] The present inventors discovered that the bactericidal activity of BLP, which belongs to the M23A subfamily protease and has glycine-glycine bond cleavage activity, can be improved by modifying specific amino acid residues in the amino acid sequence of the BLP, and thus completed the present invention.

[0010] That is, the present invention relates to the following. 1) In the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 80% identity thereto, Modification of the amino acid residue at position 116 of the amino acid sequence of SEQ ID NO:2 or a position equivalent thereto; Modification of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; Modifications of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, and 174 or equivalent in the amino acid sequence of SEQ ID NO:2; and Modification of amino acid residues at positions 116 or equivalent, 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; A polypeptide comprising any one of the modifications selected from the group consisting of: and having glycine-glycine bond decomposition activity. 2) A polynucleotide encoding the polypeptide of 1). 3) A vector or DNA fragment containing the polynucleotide of 2). 4) A transformant containing the vector or DNA fragment of 3). 5) An antibacterial agent having the polypeptide of 1) as an active ingredient. 6) An antibacterial method using the polypeptide of 1). Effect of the Invention

[0011] The polypeptide of the present invention having glycine-glycine bond decomposition activity has excellent bactericidal activity and can be used as an active ingredient of an antibacterial agent. [Brief description of the drawings]

[0012] [Figure 1] S. aureus bactericidal activity of BLP mutants. [Diagram 2] S. aureus bactericidal activity of BLP mutants. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] All patents, non-patent publications, and other publications cited herein are hereby incorporated by reference in their entirety.

[0014] As used herein, M23A subfamily proteases refer to proteases classified into the M23A subfamily, which is a subfamily of metalloproteases belonging to the M23 family, when classified according to the classification method of the MEROPS database (Rawlings, Neil D., et al. "MEROPS: the database of proteolytic enzymes, their substrates and inhibitors." Nucleic acids research 42.D1 (2013): D503-D509). As used herein, "β-lytic metallopeptidase (BLP)" refers to an enzyme also called β-lytic protease, which is a type of protease belonging to the M23A subfamily. BLP has activity of decomposing glycine-glycine bonds in peptide sequences. The activity of decomposing glycine-glycine bonds can be evaluated using methods well known in the art. For example, the activity can be determined by measuring the amount of products produced by enzymatic decomposition of a suitable substrate containing a glycine-glycine bond (e.g., an oligoglycine peptide or a FRET-GGGGG substrate described in the Examples below).

[0015] In the present specification, the identity of amino acid sequences and nucleotide sequences is calculated by the Lipman-Pearson method (Science, 1985, 227:1435-1441). Specifically, the identity is calculated by performing analysis using the search homology program of the genetic information processing software Genetyx-Win (Ver. 5.1.1; software development) with the unit size to compare (ktup) set to 2.

[0016] As used herein, "at least 80% identity" with respect to amino acid sequences and nucleotide sequences means identity of 80% or more, preferably 85% or more, more preferably 90% or more, even more preferably 92% or more, even more preferably 94% or more, even more preferably 95% or more, even more preferably 96% or more, even more preferably 98% or more, even more preferably 99% or more, and even more preferably 99.5% or more.

[0017] Unless otherwise defined herein, "one or several" used in relation to deletion, substitution, addition, or insertion of amino acids in an amino acid sequence may mean 1 to 40, preferably 1 to 30, more preferably 1 to 20, even more preferably 1 to 10, even more preferably 1 to 5, and even more preferably 1 to 3. Furthermore, unless otherwise defined herein, "one or several" used in relation to deletion, substitution, addition, or insertion of nucleotides in a nucleotide sequence may mean 1 to 120, preferably 1 to 90, more preferably 1 to 60, even more preferably 1 to 30, even more preferably 1 to 15, and even more preferably 1 to 9. In the present specification, "addition" of an amino acid or nucleotide includes addition of one or several amino acids or nucleotides to one end and both ends of a sequence.

[0018] As used herein, the "corresponding position" on an amino acid sequence or a nucleotide sequence can be determined by aligning a target sequence with a reference sequence (e.g., the amino acid sequence of SEQ ID NO: 2) to maximize homology. Alignment of amino acid sequences or nucleotide sequences can be performed using known algorithms, and the procedures are known to those skilled in the art. For example, alignment can be performed using the Clustal W multiple alignment program (Thompson, J. D. et al., 1994, Nucleic Acids Res. 22: 4673-4680) with default settings. Alternatively, Clustal W2 or Clustal omega, which are revised versions of Clustal W, can be used. Clustal W, Clustal W2 and Clustal omega can be used, for example, on the websites of the European Bioinformatics Institute (EBI [www.ebi.ac.uk / index.html]) and the DNA Data Bank of Japan (DDBJ [www.ddbj.nig.ac.jp / searches-j.html]) operated by the National Institute of Genetics. The position of the target sequence aligned to any position of the reference sequence by the above-mentioned alignment is considered to be a "position corresponding to" the any position.

[0019] Those skilled in the art can further fine-tune the alignment of the amino acid sequences obtained above to optimize it. Such an optimal alignment is preferably determined taking into consideration the identity or similarity of the amino acid sequences, the frequency of gaps to be inserted, and the like. Here, the identity or similarity of the amino acid sequences refers to the ratio (%) of the number of positions at which identical or similar amino acid residues exist in both sequences when two amino acid sequences are aligned to the total number of amino acid residues. The term "similar amino acid residues" refers to amino acid residues that have similar properties in terms of polarity and charge among the 20 types of amino acids that constitute proteins, and that cause so-called conservative substitutions. Such groups of similar amino acid residues are well known to those skilled in the art, and examples thereof include, but are not limited to, arginine and lysine; glutamic acid and aspartic acid; serine and threonine; glutamine and asparagine; leucine and isoleucine.

[0020] As used herein, the term "amino acid residue" refers to the 20 types of amino acid residues constituting proteins: alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine ​​(Cys or C), glutamine (Gln or Q), glutamic acid (Glu or E), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), and valine (Val or V).

[0021] As used herein, amino acid positions and variant descriptions may be expressed in accordance with the accepted IUPAC one-letter amino acid abbreviations as follows: The amino acid at a given position is designated as [amino acid, position], e.g., glutamine at position 116 is designated "Q116". Amino acid "substitutions" are denoted as [original amino acid, position, substituted amino acid], e.g., a substitution of histidine for glutamine at position 116 would be indicated as "Q116H". Amino acid "deletions" are designated as [original amino acid, position, Δ]. For example, a deletion of an asparagine at position 179 is designated "N179Δ". Mutants containing multiple modifications are designated by a plus sign ("+"), e.g., "Q116H+N179Δ" represents a substitution of glutamine at position 116 with histidine and a deletion of asparagine at position 179, respectively.

[0022] As used herein, the term "operably linked" between a control region such as a promoter and a gene means that the gene and the control region are linked in such a way that the gene can be expressed under the control of the control region. Procedures for "operably linked" between a gene and a control region are well known to those skilled in the art.

[0023] In this specification, "upstream" and "downstream" of a gene refer to the upstream and downstream of the transcription direction of the gene. For example, "a gene located downstream of a promoter" means that the gene is present on the 3' side of the promoter in the DNA sense strand, and "upstream" of a gene means the 5' region of the gene in the DNA sense strand.

[0024] As used herein, the term "native" when referring to a function, property, or trait of a cell is used to indicate that the function, property, or trait is inherently present in the cell. In contrast, the term "exogenous" is used to indicate a function, property, or trait that is not inherently present in the cell, but is introduced from the outside. For example, an "exogenous" gene or polynucleotide is a gene or polynucleotide that is introduced into a cell from the outside. An exogenous gene or polynucleotide may be derived from the same organism as the cell into which it is introduced, or from a different organism (i.e., a heterologous gene or polynucleotide).

[0025] As used herein, a "parent" polypeptide of a given mutant polypeptide refers to a polypeptide that becomes the mutant polypeptide by making a predetermined mutation in its amino acid residues. In other words, a "parent" polypeptide is a polypeptide before the mutation is made to the mutant polypeptide. Similarly, a "parent" polynucleotide of a mutant polynucleotide refers to a polynucleotide that becomes the mutant polynucleotide by making a predetermined mutation in its nucleotides. In other words, a "parent" polynucleotide is a polynucleotide before the mutation is made to the mutant polynucleotide.

[0026] <Polypeptide having glycine-glycine bond hydrolysis activity> The polypeptide of the present invention having glycine-glycine bond hydrolysis activity (referred to as "polypeptide of the present invention") has the following structure in the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity thereto: Modification of the amino acid residue at position 116 of the amino acid sequence of SEQ ID NO:2 or a position equivalent thereto; Modification of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; Modifications of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, and 174 or equivalent in the amino acid sequence of SEQ ID NO:2; and Modification of amino acid residues at positions 116 or equivalent, 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; A polypeptide comprising any one of the modifications selected from the group consisting of: Such a polypeptide is a mutant polypeptide in which the amino acid residues at the above-mentioned predetermined positions in the reference parent polypeptide, i.e., a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity thereto, have been modified and has activity of degrading glycine-glycine bonds in the peptide sequence. The modification of the amino acid residues at the predetermined positions is a modification for improving bactericidal activity, and therefore the polypeptide has improved bactericidal activity compared to the parent polypeptide.

[0027] In the polypeptide of the present invention, the modification site (mutation position) of the amino acid residue is as follows: position 116 of the amino acid sequence of SEQ ID NO:2 or a position equivalent thereto; positions 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; positions 170 or equivalent, 172 or equivalent, 173 or equivalent, and 174 or equivalent in the amino acid sequence of SEQ ID NO:2; and positions 116 or equivalent, 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; The position is any position selected from the group consisting of: Here, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 is a BLP derived from Achromobacter lyticus registered in the MEROPS database as MEROPS ID: M23.001. The mutation positions in the polypeptide of the present invention are numbered based on the amino acid number of the amino acid sequence.

[0028] "Parent polypeptide" refers to a reference polypeptide to which modifications are made to result in a polypeptide of the invention. The parent may be a naturally occurring (wild-type) polypeptide or a variant thereof. The parent polypeptide includes a BLP consisting of the amino acid sequence of SEQ ID NO: 2, and a polypeptide consisting of an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 2 and having glycine-glycine bond decomposition activity.

[0029] A preferred example of a polypeptide having an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 2 and having glycine-glycine bond degradation activity includes a polypeptide having an amino acid sequence having 85% or more identity with the amino acid sequence of SEQ ID NO: 2, more preferably 90% or more identity, even more preferably 92% or more identity, even more preferably 94% or more identity, even more preferably 95% or more identity, even more preferably 96% or more identity, even more preferably 98% or more identity, even more preferably 99% or more identity, even more preferably 99.5% or more identity with the amino acid sequence of SEQ ID NO: 2 and having glycine-glycine bond degradation activity. Another example of a polypeptide having an amino acid sequence having at least 80% or more identity with the amino acid sequence of SEQ ID NO: 2 and having glycine-glycine bond degradation activity includes a polypeptide having an amino acid sequence in which one or several amino acids are deleted, inserted, substituted or added to the amino acid sequence of SEQ ID NO: 2 and having glycine-glycine bond degradation activity.

[0030] Further examples of polypeptides consisting of an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 2 and having glycine-glycine bond decomposition activity include a BLP homologue derived from Lysobacter gummosus (WP_057941690.1), a BLP homologue derived from Lysobacter antibioticus (WP_057970430.1), etc.

[0031] Preferably, the parent polypeptide has Gln at or corresponding to position 116 of the amino acid sequence of SEQ ID NO:2, Tyr at or corresponding to position 170 of the amino acid sequence of SEQ ID NO:2, Tyr at or corresponding to position 172 of the amino acid sequence of SEQ ID NO:2, Tyr at or corresponding to position 173 of the amino acid sequence of SEQ ID NO:2, Val at or corresponding to position 174 of the amino acid sequence of SEQ ID NO:2, Pro at or corresponding to position 178 of the amino acid sequence of SEQ ID NO:2, or Asn at or corresponding to position 179 of the amino acid sequence of SEQ ID NO:2. More preferably, the parent BLP has Gln, Tyr, Tyr, Tyr, Val, Pro, and Asn at positions 116 or equivalent, 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent, respectively, of the amino acid sequence of SEQ ID NO:2.

[0032] The polypeptide of the present invention can be produced by modifying the amino acid residue at the predetermined position in the amino acid sequence of the parent polypeptide. The modification of the amino acid residue at the predetermined position includes substitution, insertion and / or deletion of the amino acid residue. Here, "substitution" refers to replacing an amino acid at a certain position with a different amino acid, "deletion" refers to removing an amino acid at a certain position, and "insertion" refers to adding an amino acid adjacent to and directly contiguous with the amino acid at a certain position.

[0033] From the viewpoint of improving bactericidal activity, the polypeptide of the present invention is preferably a polypeptide having at least 80% identity to the amino acid sequence of SEQ ID NO: 2 and having glycine-glycine bond decomposition activity. Furthermore, the polypeptide may contain any number of conservative amino acid substitutions as long as it retains the properties of the above-mentioned polypeptide.

[0034] In the present invention, a modification of the amino acid residue at position 116 or a position equivalent thereto in the amino acid sequence of SEQ ID NO:2 is preferably a substitution with His or Asn; a modification of the amino acid residue at position 170 or a position equivalent thereto is preferably a substitution with Ser; a modification of the amino acid residue at position 172 or a position equivalent thereto is preferably a substitution with Trp; a modification of the amino acid residue at position 173 or a position equivalent thereto is preferably a substitution with Phe; a modification of the amino acid residue at position 174 or a position equivalent thereto is preferably a substitution with Thr; a modification of the amino acid residue at position 178 or a position equivalent thereto is preferably a substitution with His; and a modification of the amino acid residue at position 179 or a position equivalent thereto is preferably a deletion of the amino acid residue.

[0035] Thus, preferably, the polypeptide of the present invention comprises, in the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 80% identity thereto, Substitution of the amino acid residue at position 116 of the amino acid sequence of SEQ ID NO:2 or a position equivalent thereto with His; Substitution of the amino acid residue at position 116 of the amino acid sequence of SEQ ID NO:2 or a position equivalent thereto with Asn; substitution of the amino acid residue at position 170 or a position equivalent thereto in the amino acid sequence of SEQ ID NO:2 with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr, substitution of the amino acid residue at position 178 or a position equivalent thereto with His, and deletion of the amino acid residue at position 179 or a position equivalent thereto; Substitution of the amino acid residue at position 170 or a corresponding position of the amino acid sequence of SEQ ID NO:2 with Ser, substitution of the amino acid residue at position 172 or a corresponding position with Trp, substitution of the amino acid residue at position 173 or a corresponding position with Phe, and substitution of the amino acid residue at position 174 or a corresponding position with Thr; and substitution of the amino acid residue at position 116 or a position equivalent thereto in the amino acid sequence of SEQ ID NO:2 with His, substitution of the amino acid residue at position 170 or a position equivalent thereto with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr, substitution of the amino acid residue at position 178 or a position equivalent thereto with His, and deletion of the amino acid residue at position 179 or a position equivalent thereto, and having glycine-glycine bond decomposition activity.

[0036] In one embodiment, the polypeptide of the present invention has an His at position 116 or a position equivalent thereto in the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity thereto, and has glycine-glycine bond hydrolysis activity. In another embodiment, the polypeptide of the present invention has an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO:2, has Asn at position 116 of the amino acid sequence of SEQ ID NO:2 or a position corresponding thereto, and has glycine-glycine bond hydrolysis activity. In another embodiment, the polypeptide of the present invention, in the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity thereto, has Ser at or a position equivalent to 170 of the amino acid sequence of SEQ ID NO: 2, Trp at or a position equivalent to 172, Phe at or a position equivalent to 173, Thr at or a position equivalent to 174, His at or a position equivalent to 178, and a deletion of the amino acid residue at or a position equivalent to 179, and has glycine-glycine bond hydrolysis activity. In another embodiment, the polypeptide of the present invention has, in the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity thereto, Ser at or a position equivalent to 170, Trp at or a position equivalent to 172, Phe at or a position equivalent to 173, and Thr at or a position equivalent to 174 of the amino acid sequence of SEQ ID NO: 2, and has glycine-glycine bond decomposition activity. In another embodiment, the polypeptide of the present invention, in the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity thereto, has His at position 116 or a position equivalent thereto, Ser at position 170 or a position equivalent thereto, Trp at position 172 or a position equivalent thereto, Phe at position 173 or a position equivalent thereto, Thr at position 174 or a position equivalent thereto, His at position 178 or a position equivalent thereto, and a deletion of the amino acid residue at position 179 or a position equivalent thereto, and has glycine-glycine bond hydrolysis activity.

[0037] <Polynucleotide encoding the polypeptide of the present invention> The polypeptide of the present invention can be produced by modifying the parent polypeptide as described above using various mutagenesis techniques known in the art. For example, the polypeptide can be produced by mutating a polynucleotide encoding an amino acid residue to be modified in a polynucleotide encoding the amino acid sequence of the parent polypeptide to a polynucleotide encoding the amino acid residue after modification, and then expressing the polypeptide from the mutated gene.

[0038] In the present invention, various mutagenesis techniques known in the art can be used as a means for mutating amino acid residues in a parent polypeptide. For example, a polynucleotide encoding the polypeptide of the present invention can be obtained by mutating a nucleotide sequence encoding an amino acid residue to be mutated in a polynucleotide encoding the amino acid sequence of a parent polypeptide (hereinafter also referred to as a parent gene) to a nucleotide sequence encoding the amino acid residue after the mutation.

[0039] The introduction of a desired mutation into a parent gene can basically be carried out using various site-directed mutagenesis methods well known to those skilled in the art. Site-directed mutagenesis can be carried out by any method, such as inverse PCR or annealing. Commercially available site-directed mutagenesis kits (e.g., Stratagene's QuickChange II Site-Directed Mutagenesis Kit, QuickChange Multi Site-Directed Mutagenesis Kit, etc.) can also be used.

[0040] Site-specific mutagenesis of a parent gene can be most commonly performed using a mutagenesis primer containing the nucleotide mutation to be introduced. The mutagenesis primer can be designed to anneal to a region containing a nucleotide sequence encoding the amino acid residue to be mutated in the parent gene, and to contain a nucleotide sequence having a nucleotide sequence (codon) encoding the mutated amino acid residue instead of the nucleotide sequence (codon) encoding the amino acid residue to be mutated. Those skilled in the art can appropriately recognize and select the nucleotide sequences (codons) encoding the amino acid residues before and after the mutation based on ordinary textbooks, etc. Alternatively, site-specific mutagenesis can be performed by a method in which DNA fragments obtained by amplifying the upstream and downstream sides of the mutation site using two complementary primers containing the nucleotide mutation to be introduced separately are linked together by SOE (splicing by overlap extension)-PCR (Gene, 1989, 77(1): p61-68).

[0041] A template DNA containing a parent gene can be prepared by extracting genomic DNA from a microorganism that produces the above-mentioned BLP or BLP homologue by a conventional method, or by extracting RNA and synthesizing cDNA by reverse transcription. Alternatively, a corresponding nucleotide sequence may be chemically synthesized based on the amino acid sequence of the parent polypeptide and used as the template DNA. A DNA sequence containing a nucleotide sequence encoding a BLP consisting of the amino acid sequence of SEQ ID NO:2 is shown in SEQ ID NO:1. In the nucleotide sequence of SEQ ID NO:1, the nucleotide sequence at positions 595 to 1134 is the nucleotide sequence encoding a BLP consisting of the amino acid sequence of SEQ ID NO:2.

[0042] The mutation primer can be prepared by a well-known oligonucleotide synthesis method such as the phosphoramidite method (Nucleic Acids Research, 1989, 17:7059-7071). Such primer synthesis can also be performed using, for example, a commercially available oligonucleotide synthesizer (such as that manufactured by ABI). A primer set including the mutation primer is used to perform site-specific mutagenesis as described above using a parent gene as a template DNA, thereby obtaining a polynucleotide encoding the polypeptide of the present invention having the desired mutation.

[0043] The polynucleotide encoding the polypeptide of the present invention may comprise single-stranded or double-stranded DNA, cDNA, RNA or other artificial nucleic acid. The DNA, cDNA and RNA may be chemically synthesized. The polynucleotide may also comprise a nucleotide sequence of an untranslated region (UTR) in addition to an open reading frame (ORF). The polynucleotide may also be codon-optimized according to the species of the transformant used to produce the polypeptide of the present invention. Information on codons used by various organisms is available from the Codon Usage Database ([www.kazusa.or.jp / codon / ]).

[0044] BLP is first expressed as a proprotein, and the proregion is cleaved by self-processing to convert it into a mature protein. The proregion refers to a region that contributes to the formation of the three-dimensional structure of the mature protein region located downstream of the proregion on the proprotein. Therefore, another example of a polynucleotide encoding the polypeptide of the present invention includes a polynucleotide in which a polynucleotide encoding a polypeptide functioning as a proregion of BLP is linked upstream of the polynucleotide encoding the polypeptide of the present invention. Examples of the polynucleotide encoding the polypeptide functioning as a proregion of BLP include a polynucleotide consisting of the nucleotide sequence of positions 73 to 594 of SEQ ID NO: 1, a polynucleotide having at least 80% identity with the nucleotide sequence of positions 73 to 594 of SEQ ID NO: 1 and consisting of a nucleotide sequence encoding a polypeptide functioning as a proregion of BLP, and a polynucleotide consisting of a nucleotide sequence in which one or several nucleotides are deleted, substituted, inserted or added to the nucleotide sequence of positions 73 to 594 of SEQ ID NO: 1 and encoding a polypeptide functioning as a proregion of BLP. Further examples of polynucleotides encoding the polypeptides of the present invention include polynucleotides in which a polynucleotide encoding a polypeptide functioning as a secretory signal and pro-region of BLP is linked upstream of the polynucleotide encoding the polypeptide of the present invention. Examples of the polynucleotide encoding the polypeptide functioning as a secretory signal and pro-region of BLP include a polynucleotide consisting of the nucleotide sequence of positions 1 to 594 of SEQ ID NO: 1, a polynucleotide having at least 80% identity with the nucleotide sequence of positions 1 to 594 of SEQ ID NO: 1 and encoding a polypeptide functioning as a secretory signal and pro-region of BLP, and a polynucleotide consisting of a nucleotide sequence in which one or several nucleotides have been deleted, substituted, inserted or added to the nucleotide sequence of positions 1 to 594 of SEQ ID NO: 1 and encoding a polypeptide functioning as a secretory signal and pro-region of BLP.

[0045] <Vector or DNA fragment> The obtained polynucleotide encoding the polypeptide of the present invention can be incorporated into a vector. The vector containing the polynucleotide is capable of stably retaining the gene, maintaining replication in a host microorganism, and stably expressing the polypeptide of the present invention. Examples of such vectors include shuttle vectors such as pHA3040SP64, pHSP64R, or pASP64 (Patent No. 3492935), pHY300PLK (an expression vector capable of transforming both Escherichia coli and Bacillus subtilis; Jpn J Genet, 1985, 60:235-243), and pAC3 (Nucleic Acids Res, 1988, 16:8732); and vectors usable for transformation of Bacillus bacteria such as pUB110 (J Bacteriol, 1978, 134:318-329), and pTA10607 (Plasmid, 1987, 18:8-15). Also, vectors derived from Escherichia coli (e.g., pET22b(+), pBR322, pBR325, pUC57, pUC118, pUC119, pUC18, pUC19, pBluescript, etc.) can be used. Among these, from the viewpoint of the efficiency of producing the polypeptide of the present invention, vectors that can be used for transformation of bacteria of the genus Bacillus are preferred.

[0046] The vector may contain a DNA region containing a DNA replication origin or a replication origin. Alternatively, the vector may be operably linked upstream of the polynucleotide encoding the polypeptide of the present invention to a control sequence such as a promoter region for initiating transcription of the gene, a terminator region, or a secretion signal region for secreting the expressed protein outside the cell.

[0047] The types of the control sequences such as the promoter region, terminator, and secretion signal region are not particularly limited, and promoters and secretion signal sequences that are commonly used can be appropriately selected and used depending on the host to be introduced. For example, suitable examples of the control sequences that can be incorporated into the vector include the promoter and secretion signal sequence of the cellulase gene of Bacillus sp. KSM-S237 strain.

[0048] Alternatively, the vector of the present invention may further incorporate a marker gene (e.g., a resistance gene to a drug such as ampicillin, neomycin, kanamycin, or chloramphenicol) for selecting a host into which the vector has been appropriately introduced. Alternatively, when an auxotrophic strain is used as a host, a gene encoding an enzyme for synthesizing the required nutrient may be incorporated as a marker gene into the vector. Furthermore, when a selective medium requiring a specific metabolism for growth is used, a gene related to the metabolism may be incorporated as a marker gene into the vector. An example of such a metabolism-related gene is the acetamidase gene for utilizing acetamide as a nitrogen source.

[0049] The polynucleotide encoding the polypeptide of the present invention can be ligated to a control sequence and a marker gene by a method known in the art, such as splicing by overlap extension (SOE)-PCR (Gene, 1989, 77:61-68). The procedure for introducing the ligated fragment into a vector is well known in the art.

[0050] <Transformants> The transformant of the present invention can be obtained by introducing a vector containing a polynucleotide encoding the polypeptide of the present invention into a host, or by introducing a DNA fragment containing a polynucleotide encoding the polypeptide of the present invention into the genome of the host.

[0051] The host microorganism is not particularly limited, and examples thereof include gram-positive bacteria such as Bacillus genus (e.g., Bacillus subtilis), gram-negative bacteria such as Escherichia coli, and fungi such as Streptomyces genus, Saccharomyces genus (yeast), and Aspergillus genus (mold). Preferred hosts are microorganisms of the same species or genus as the bacteria from which the parent gene encoding the amino acid sequence of the parent polypeptide of the polypeptide of the present invention to be introduced into the host is derived, Escherichia coli, or Bacillus genus bacteria, and more preferably Bacillus genus bacteria. Furthermore, Bacillus genus bacteria that produce less proteases other than the polypeptide of the present invention to be introduced are preferred. Preferred examples thereof include Bacillus subtilis strains in which one or more genes selected from aprX, aprE, nprB, nprE, vpr, mpr, epr, and wprA of Bacillus subtilis have been deleted or inactivated.

[0052] The method for introducing a vector into a host can be a method commonly used in the field, such as the competent cell method, electroporation method, protoplast method, particle gun method, PEG method, etc. By selecting a strain in which the vector has been appropriately introduced using the expression of a marker gene, nutritional requirements, etc. as an indicator, a desired transformant into which the vector has been introduced can be obtained.

[0053] Alternatively, a fragment in which a polynucleotide encoding the polypeptide of the present invention, a control sequence, and a marker gene are linked can be directly introduced into the genome of a host. For example, a DNA fragment in which sequences complementary to the host genome are added to both ends of the linked fragment is constructed by SOE-PCR or the like, and this is introduced into a host to cause homologous recombination between the host genome and the DNA fragment, thereby introducing the polynucleotide encoding the polypeptide of the present invention into the genome of the host.

[0054] When the thus obtained transformant into which the polynucleotide encoding the polypeptide of the present invention or a vector containing the same has been introduced is cultured in an appropriate medium, the gene encoding the protein on the vector is expressed to produce the polypeptide of the present invention. The medium used for culturing the transformant can be appropriately selected by those skilled in the art depending on the type of the microorganism of the transformant.

[0055] Alternatively, the polypeptide of the present invention may be expressed from a polynucleotide encoding the polypeptide of the present invention or a transcription product thereof using a cell-free translation system. The term "cell-free translation system" refers to an in vitro transcription / translation system or an in vitro translation system that is constructed by adding reagents such as amino acids necessary for protein translation to a suspension obtained by mechanically disrupting host cells.

[0056] The polypeptide of the present invention produced in the above culture or cell-free translation system can be isolated or purified by using a general method used for protein purification, such as centrifugation, ammonium sulfate precipitation, gel chromatography, ion exchange chromatography, affinity chromatography, etc., either alone or in appropriate combination. In this case, if the gene encoding the polypeptide of the present invention is operably linked to a secretory signal sequence on a vector in the transformant, the produced protein is secreted outside the cell, and can be more easily recovered from the culture. The protein recovered from the culture may be further purified by known means.

[0057] <Antibacterial agent> As mentioned above, BLP is known to have bacteriolytic activity against gram-positive bacteria (Non-Patent Documents 3 and 4). Furthermore, as shown in the Examples below, the polypeptide of the present invention has improved bactericidal activity by bacteriolysis compared to the parent polypeptide. Therefore, the polypeptide of the present invention is useful as an antibacterial enzyme and can be an antibacterial agent. It can also be used to produce an antibacterial agent. That is, the polypeptide of the present invention can be used for antibacterial purposes.

[0058] In the present invention, the term "antibacterial" includes the concepts of "bacteriolysis", "sterilization", and "sterilization" which kill microorganisms, and "bacteriostasis" and "bacteriostatic" which suppress the occurrence, growth, and proliferation of microorganisms. A preferred example of the antibacterial agent is a bactericide. The antibacterial or bactericidal activity can be evaluated by a method well known in the art, for example, by adding a test bacterium to a test solution containing the target enzyme and treating for a predetermined period of time, then serially diluting the test solution and culturing it in an appropriate solid medium, and counting the number of colonies formed to calculate the number of viable bacteria.

[0059] The above-mentioned "use" may be applied to humans, non-human animals, specimens derived therefrom, and articles. Use on humans or non-human animals may be therapeutic or non-therapeutic. "Non-therapeutic" is a concept that does not include medical procedures, that is, a concept that does not include a method of operating, treating, or diagnosing humans, more specifically, a concept that does not include a method of operating, treating, or diagnosing humans by a doctor or a person under the instruction of a doctor. Examples of the above-mentioned articles include daily necessities, medical supplies, home appliances, electrical appliances, building materials (doors, doors, doorknobs, etc.), and housing equipment (bathrooms, kitchens, washrooms, toilets, etc.).

[0060] The bacteria against which the antibacterial agent of the present invention exhibits antibacterial activity are preferably gram-positive bacteria. Examples of gram-positive bacteria include, but are not limited to, staphylococci such as Staphylococcus aureus and Staphylococcus epidermidis; streptococci such as Streptococcus pneumoniae, Streptococcus viridans, Group A β-hemolytic streptococcus, and Group B β-hemolytic streptococcus; Enterococcus bacteria such as Enterococcus faecalis; Bacillus bacteria such as Bacillus anthracis; Clostridium bacteria such as Clostridium tetani, Clostridium perfringens, and Clostridium botulinum; Corynebacterium diphtheriae and the like; Listeria monocytogenes and the like. Among these, Staphylococcus aureus is more preferable, and Staphylococcus aureus is even more preferable.

[0061] The antibacterial agent of the present invention may be the polypeptide of the present invention alone, or may be an enzyme composition containing the polypeptide.

[0062] The content of the polypeptide of the present invention in the enzyme composition is not particularly limited as long as it shows antibacterial activity, but is, for example, preferably 0.00001% by mass or more, more preferably 0.0002% by mass or more, even more preferably 0.0005% by mass or more, even more preferably 0.001% by mass or more, even more preferably 0.005% by mass or more, and even more preferably 0.01% by mass or more, and is preferably 10% by mass or less, more preferably 1% by mass or less, and even more preferably 0.5% by mass or less, based on the total mass of the composition. In addition, the content is preferably 0.00001 to 10% by mass, more preferably 0.0002 to 1% by mass, more preferably 0.0005 to 0.5% by mass, even more preferably 0.001 to 0.5% by mass, even more preferably 0.005 to 0.5% by mass, and even more preferably 0.01 to 0.5% by mass.

[0063] The antibacterial agent of the present invention can be used as a medicine, quasi-drug, cosmetic, daily necessities, reagent, etc. that is effective against antibacterial properties, or as a material for imparting antibacterial properties to various products such as medicines, quasi-drugs, cosmetics, daily necessities, reagents, foods, etc. In particular, the antibacterial agent of the present invention is preferably used as a medicine, quasi-drug, or cosmetic, or as a material to be incorporated into a medicine, quasi-drug, or cosmetic, and from the viewpoint of being suitable for such a medicine, quasi-drug, or cosmetic, it is more preferable to use it as an external preparation.

[0064] The antibacterial agent of the present invention may be in a liquid, semi-solid, or solid form, or may be impregnated into a substrate such as a sheet, but when the antibacterial agent of the present invention is an external preparation, specific forms thereof include ointments, creams, emulsions, gels, external liquid preparations, lotions, sprays, external aerosol preparations, pump sprays, patches, tapes, poultices, external solid preparations, external powders, liniments, etc. The antibacterial agent of the present invention may also be in the form of a facial cleanser, skin lotion, lotion, emulsion, cream, mist, spray, face mask, body soap, shampoo, hair tonic, cleanser, bath additive, soap, dentifrice, mouthwash, wet tissue, face wash sheet, body sheet, etc.

[0065] Such preparations can be obtained by mixing and dispersing the polypeptide directly or together with a pharma- ceutically acceptable carrier, such as various oils, surfactants, gelling agents, preservatives, antioxidants, solvents, alcohols, water, chelating agents, thickeners, UV absorbers, emulsion stabilizers, moisturizers, pH adjusters, colorants, fragrances, etc., using a general production method, and then processing the mixture into a desired form. Furthermore, such preparations can be appropriately formulated with antibacterial agents, plant extracts, anti-inflammatory agents, cooling agents, etc. other than the polypeptide of the present invention, as necessary, within the scope of not interfering with the effects of the present invention.

[0066] The antibacterial agent of the present invention can kill bacteria on an object or suppress the occurrence, growth, and proliferation of bacteria by contacting the object. The manner of contacting the antibacterial agent with the object is not particularly limited, but examples include adding, applying, or spraying the antibacterial agent to the surface of the object, immersing the object in the antibacterial agent, and washing the object with the antibacterial agent. Examples of objects include the above-mentioned humans and non-human animals that require antibacterial treatment, specimens derived from them, and articles, etc., in which bacteria are present, may be present, or may be attached to the object.

[0067] In another aspect, the present invention provides a method for improving the antibacterial activity of a polypeptide having glycine-glycine bond decomposition activity, comprising: Modification of the amino acid residue at position 116 of the amino acid sequence of SEQ ID NO:2 or a position equivalent thereto; Modification of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; Modifications of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, and 174 or equivalent in the amino acid sequence of SEQ ID NO:2; and Modification of amino acid residues at positions 116 or equivalent, 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; The details of the modification in this method are the same as those in the above-mentioned modification of the polypeptide of the present invention.

[0068] In relation to the above-described embodiment, the present invention further discloses the following aspects. <1> 2 or an amino acid sequence having at least 80% identity thereto, Modification of the amino acid residue at position 116 of the amino acid sequence of SEQ ID NO:2 or a position equivalent thereto; Modification of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; Modifications of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, and 174 or equivalent in the amino acid sequence of SEQ ID NO:2; and Modification of amino acid residues at positions 116 or equivalent, 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; A polypeptide comprising any one of the modifications selected from the group consisting of: and having glycine-glycine bond decomposition activity. <2> The modification is as follows: Substitution of the amino acid residue at position 116 of the amino acid sequence shown in SEQ ID NO:2 or a position equivalent thereto with His; Substitution of the amino acid residue at position 116 of the amino acid sequence shown in SEQ ID NO:2 or a position equivalent thereto with Asn; substitution of the amino acid residue at position 170 or a position equivalent thereto in the amino acid sequence shown in SEQ ID NO:2 with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr, substitution of the amino acid residue at position 178 or a position equivalent thereto with His, and deletion of the amino acid residue at position 179 or a position equivalent thereto; Substitution of the amino acid residue at position 170 or a position equivalent thereto in the amino acid sequence shown in SEQ ID NO:2 with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, and substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr; and substitution of the amino acid residue at position 116 or a position equivalent thereto in the amino acid sequence shown in SEQ ID NO:2 with His, substitution of the amino acid residue at position 170 or a position equivalent thereto with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr, substitution of the amino acid residue at position 178 or a position equivalent thereto with His, and deletion of the amino acid residue at position 179 or a position equivalent thereto, Any modification selected from the group consisting of: <1> The polypeptide described. <3> The polypeptide has an His at position 116 or a position corresponding thereto in the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity thereto, and has a glycine-glycine bond hydrolysis activity. <1> or <2> The polypeptide described. <4> The polypeptide has an Asn at position 116 of the amino acid sequence of SEQ ID NO:2 or a position corresponding thereto in an amino acid sequence having at least 80% identity thereto, and has a glycine-glycine bond hydrolysis activity. <1> or <2> The polypeptide described. <5> A polypeptide, in which, in the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 80% identity thereto, the polypeptide has Ser at or corresponding to position 170 of the amino acid sequence of SEQ ID NO:2, Trp at or corresponding to position 172, Phe at or corresponding to position 173, Thr at or corresponding to position 174, His at or corresponding to position 178, and an amino acid residue at or corresponding to position 179 is deleted, and the polypeptide has glycine-glycine bond hydrolysis activity. <1> or <2> The polypeptide described. <6> A polypeptide having, in the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 80% identity thereto, Ser at or a position corresponding thereto, Trp at or a position corresponding thereto, Phe at or a position corresponding thereto, and Thr at or a position corresponding thereto in the amino acid sequence of SEQ ID NO:2, and having a glycine-glycine bond hydrolysis activity. <1> or <2> The polypeptide described. <7> A polypeptide, in which, in the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 80% identity thereto, the polypeptide has His at or corresponding to position 116 of the amino acid sequence of SEQ ID NO:2, Ser at or corresponding to position 170, Trp at or corresponding to position 172, Phe at or corresponding to position 173, Thr at or corresponding to position 174, His at or corresponding to position 178, and an amino acid residue at or corresponding to position 179 is deleted, and the polypeptide has glycine-glycine bond hydrolysis activity. <1> or <2> The polypeptide described. <8> The sequence identity is 90% or more. <1> ~ <7> 2. The polypeptide according to claim 1 , <9> have improved antibacterial activity compared to the parent polypeptide, <1> ~ <8> 2. The polypeptide according to claim 1 , <10> The antibacterial activity is against gram-positive bacteria. <9> The polypeptide described. <11> The antibacterial activity is an antibacterial activity against Staphylococcus aureus. <9> or <10> The polypeptide described. <12> The antibacterial activity is an antibacterial activity against Staphylococcus aureus. <9> ~ <11> 2. The polypeptide according to claim 1 ,

[0069] <13> 2 or an amino acid sequence having at least 80% identity thereto, Modification of the amino acid residue at position 116 of the amino acid sequence of SEQ ID NO:2 or a position equivalent thereto; Modification of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; Modifications of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, and 174 or equivalent in the amino acid sequence of SEQ ID NO:2; and Modification of amino acid residues at positions 116 or equivalent, 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; A method for producing a polypeptide having glycine-glycine bond decomposition activity, comprising carrying out any modification selected from the group consisting of: <14> The modification is as follows: Substitution of the amino acid residue at position 116 of the amino acid sequence shown in SEQ ID NO:2 or a position equivalent thereto with His; Substitution of the amino acid residue at position 116 of the amino acid sequence shown in SEQ ID NO:2 or a position equivalent thereto with Asn; substitution of the amino acid residue at position 170 or a position equivalent thereto in the amino acid sequence shown in SEQ ID NO:2 with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr, substitution of the amino acid residue at position 178 or a position equivalent thereto with His, and deletion of the amino acid residue at position 179 or a position equivalent thereto; Substitution of the amino acid residue at position 170 or a position equivalent thereto in the amino acid sequence shown in SEQ ID NO:2 with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, and substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr; and substitution of the amino acid residue at position 116 or a position equivalent thereto in the amino acid sequence shown in SEQ ID NO:2 with His, substitution of the amino acid residue at position 170 or a position equivalent thereto with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr, substitution of the amino acid residue at position 178 or a position equivalent thereto with His, and deletion of the amino acid residue at position 179 or a position equivalent thereto, Any modification selected from the group consisting of: <13> The method described.

[0070] <15> <1> ~ <12> A polynucleotide encoding any one of the polypeptides described above. <16> <15> A vector or DNA fragment comprising the polynucleotide described. <17> <16> A transformant containing the vector or DNA fragment described above. <18> It is a microorganism, <17> The transformant described herein. <19> Bacillus genus bacteria <17> or <18> The transformant described herein.

[0071] <20> <1> ~ <12> 13. An antibacterial agent comprising as an active ingredient the polypeptide according to any one of claims 1 to 12. <21> It is an antibacterial agent against gram-positive bacteria. <20> The antibacterial agent described herein. <22> It is an antibacterial agent against staphylococci. <20> or <21> The antibacterial agent described herein. <23> It is an antibacterial agent against Staphylococcus aureus. <20> ~ <22> 13. The antibacterial agent according to any one of claims 1 to 12. <24> It is a bactericide, <20> ~ <23> 13. The antibacterial agent according to any one of claims 1 to 12. <25> It is an external preparation. <20> ~ <24> 13. The antibacterial agent according to any one of claims 1 to 12. <26> For the manufacture of antibacterial agents, <1> ~ <12> 2. Use of the polypeptide according to any one of claims 1 to 11. <27> For antibacterial use, <1> ~ <12> 2. The polypeptide according to claim 1 , <28> <1> ~ <12> 2. An antibacterial method using the polypeptide according to any one of claims 1 to 11. <29> For antibacterial, <1> ~ <12> 2. Use of the polypeptide according to any one of claims 1 to 11. <30> An antibacterial method comprising: <1> ~ <12> A method comprising contacting a polypeptide of any one of claims 1 to 4 with a polypeptide of any one of claims 1 to 4. <31> An antibacterial method comprising: <20> ~ <25> The method comprises contacting the composition with an antibacterial agent according to any one of claims 1 to 5.

[0072] <32> 2 or an amino acid sequence having at least 80% identity thereto, Modification of the amino acid residue at position 116 of the amino acid sequence of SEQ ID NO:2 or a position equivalent thereto; Modification of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; Modifications of amino acid residues at positions 170 or equivalent, 172 or equivalent, 173 or equivalent, and 174 or equivalent in the amino acid sequence of SEQ ID NO:2; and Modification of amino acid residues at positions 116 or equivalent, 170 or equivalent, 172 or equivalent, 173 or equivalent, 174 or equivalent, 178 or equivalent, and 179 or equivalent in the amino acid sequence of SEQ ID NO:2; A method for improving the antibacterial activity of a polypeptide having glycine-glycine activity, comprising carrying out any modification selected from the group consisting of: <33> The modification is as follows: Substitution of the amino acid residue at position 116 of the amino acid sequence shown in SEQ ID NO:2 or a position equivalent thereto with His; Substitution of the amino acid residue at position 116 of the amino acid sequence shown in SEQ ID NO:2 or a position equivalent thereto with Asn; substitution of the amino acid residue at position 170 or a position equivalent thereto in the amino acid sequence shown in SEQ ID NO:2 with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr, substitution of the amino acid residue at position 178 or a position equivalent thereto with His, and deletion of the amino acid residue at position 179 or a position equivalent thereto; Substitution of the amino acid residue at position 170 or a position equivalent thereto in the amino acid sequence shown in SEQ ID NO:2 with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, and substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr; and substitution of the amino acid residue at position 116 or a position equivalent thereto in the amino acid sequence shown in SEQ ID NO:2 with His, substitution of the amino acid residue at position 170 or a position equivalent thereto with Ser, substitution of the amino acid residue at position 172 or a position equivalent thereto with Trp, substitution of the amino acid residue at position 173 or a position equivalent thereto with Phe, substitution of the amino acid residue at position 174 or a position equivalent thereto with Thr, substitution of the amino acid residue at position 178 or a position equivalent thereto with His, and deletion of the amino acid residue at position 179 or a position equivalent thereto, Any modification selected from the group consisting of: <32> The method described. EXAMPLES

[0073] Example 1 Preparation of BLP mutants (1) Construction of BLP mutant expression plasmids A forward primer having a 15-base complementary sequence with the reverse primer at the 5'-end and containing the mutant sequence, and a reverse primer having the base immediately preceding the mutant sequence at the 5'-end were used as a primer pair for introducing mutations. PCR was performed using the primer pair for introducing mutations, with the plasmid pHY-BLP2 described in Example 1 of WO 2019 / 142773 as a template. When multiple fragments were ligated, an In-Fusion reaction was performed using each PCR product according to the protocol of the In-Fusion, HD Cloning kit (Clontech). The PCR product or the In-Fusion reaction solution was transformed into Bacillus subtilis by the protoplast method to obtain a transformant carrying the desired BLP mutant expression plasmid.

[0074] (2) Enzyme production culture The transformant colony obtained in (1) was inoculated into 1 mL of LB medium supplemented with tetracycline to a final concentration of 15 ppm, and then cultured overnight at 30° C. and 150 spm. The next day, 400 μL of the culture was inoculated into 5 mL of 2×L-maltose medium (2% tryptone, 1% yeast extract, 1% NaCl, 7.5% maltose, 7.5 ppm manganese sulfate pentahydrate, 21 μM ZnSO4, 15 ppm tetracycline; % is (w / v)%) and cultured for 2 days at 30° C. and 150 spm, and the culture supernatant containing the enzyme produced by the bacteria was collected by centrifugation.

[0075] (3) Measurement of enzyme activity The substrate used was a FRET substrate with pentaglycine between the fluorescent group Nma and the quenching group Lys(Dpn) [hereinafter referred to as FRET-GGGGG] (made to order by PH Japan). Here, Nma refers to 2-(N-methylamino)benzoyl (Nma). Lys(Dpn) refers to a substrate with 2,4-dinitrophenyl (Dnp) in the side chain of lysine (Lys). 2 μL of enzyme solution (diluted appropriately) and 200 μL of 20 mM Tris-HCl (pH 7.5) were added to a 96-well black plate, and 10 μL of FRET-GGGGG solution (1 mM FRET-GGGGG, 100 mM Tris-HCl (pH 7.5)) was added to prepare a reaction solution. The fluorescence intensity of the reaction solution was measured over time using infinite M200 (TECAN) at a temperature of 30°C, an excitation wavelength of 340 nm, and a measurement wavelength of 440 nm. Under the same reaction conditions, the fluorescence intensity of the reaction solution was measured using 20 mM Tris-HCl (pH 7.5) instead of the enzyme solution, and equimolar solutions of FRETS-25-STD1 and FRETS-25-STD2 (Peptide Institute) instead of FRET-GGGGG, and a calibration curve was created. The activity of 1 unit (U) was defined as the amount of enzyme required to show a change in fluorescence intensity of X / min, when the fluorescence intensity of a solution containing 1 μmol FRETS-25-STD1 and 1 μmol FRETS-25-STD2 was X. The FRET-GGGGG decomposition activity (U / mL) of the enzyme solution was calculated.

[0076] (4) Purification of enzyme from culture supernatant BLP and its mutants were purified from the culture supernatant obtained in (2). The culture supernatant was buffer-exchanged with 10 mM citrate-Na pH 6 using Amicon Ultra 10K molecular weight cutoff (Merck Millipore). The enzyme was purified from the buffer-exchanged liquid using AKTA explorer 10S (GE Healthcare). First, the liquid obtained by the buffer exchange was passed through a TOYOPEARL Gigacap CM-650M column (Tosoh), and then the adsorbed components were eluted using an elution buffer (10 mM citrate-Na pH 6, 200 mM NaCl). Among the eluted fractions, fractions that showed FRET-GGGGG decomposition activity by the activity measurement method in (3) were collected. The collected fractions were buffer-exchanged with 20 mM Tris-HCl (pH 7.5) solution using Amicon Ultra 10K molecular weight cutoff, and each enzyme solution containing BLP and its mutants was obtained.

[0077] (5) Measurement of enzyme solution concentration The concentration of the enzyme solution was measured using a DC Protein Assay Kit (Bio-Rad). BSA Standard Solution (WAKO) was used as the standard solution for calculating the protein amount.

[0078] Example 2 Staphylococcus aureus killing test Staphylococcus aureus ATCC6538 was used as the test bacteria. The SCD liquid medium was SCD medium "Daigo" for general bacterial testing (Fujifilm Wako Pure Chemicals), the SCD agar medium was SCD agar medium "Daigo" for general bacterial testing (Fujifilm Wako Pure Chemicals), the LP diluent was LP diluent "Daigo" (Fujifilm Wako Pure Chemicals), and the buffer was 20 mM Tris-HCl (pH 7.5). Buffers containing each enzyme at a final concentration of 0.5 ppm were used as the test liquid. The test bacteria were cultured overnight with shaking in SCD liquid medium at 37°C, harvested, washed and resuspended in buffer, and then diluted with 10 8-9The concentration was adjusted to CFU / mL. 5 μL of the bacterial solution was added to 500 μL of each test solution and incubated at 30°C for 30 minutes. The test solution was serially diluted with LP dilution solution and 100 μL of each solution was applied to SCD agar medium. After incubation at 37°C for 24 hours, the number of colonies was counted to calculate the number of viable bacteria (CFU / mL) contained in 1 mL of test solution. Compared to wild-type BLP, the mutants Q116H, Q116N, Y170S+Y172W+Y173F+V174T+P178H+N179Δ, and Y170S+Y172W+Y173F+V174T had improved bactericidal activity against S. aureus (Fig. 1). Furthermore, the combination of the Q116H and Y170S+Y172W+Y173F+V174T+P178H+N179Δ mutations further improved bactericidal activity against S. aureus (Fig. 2).

Claims

1. A polypeptide having glycine-glycine bond decomposition activity, It consists of an amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO:2, the below described: A polypeptide having His at a position corresponding to position 116 of the amino acid sequence of SEQ ID NO:2; A polypeptide having an Asn at a position corresponding to position 116 of the amino acid sequence of SEQ ID NO:2; A polypeptide having Ser at the position corresponding to position 170, Trp at the position corresponding to position 172, Phe at the position corresponding to position 173, Thr at the position corresponding to position 174, His at the position corresponding to position 178, and no amino acid residue at the position corresponding to position 179 of the amino acid sequence of SEQ ID NO:2; A polypeptide having Ser at position 170, Trp at position 172, Phe at position 173, and Thr at position 174 of the amino acid sequence of SEQ ID NO:2; and A polypeptide having His at a position corresponding to position 116, Ser at a position corresponding to position 170, Trp at a position corresponding to position 172, Phe at a position corresponding to position 173, Thr at a position corresponding to position 174, His at a position corresponding to position 178, and no amino acid residue at a position corresponding to position 179 in the amino acid sequence of SEQ ID NO:

2. any polypeptide selected from the group consisting of Improved antibacterial activity compared to the parent polypeptide; the parent polypeptide is a polypeptide having an amino acid sequence having Gln, Tyr, Tyr, Tyr, Val, Pro, and Asn at positions corresponding to positions 116, 170, 172, 173, 174, 178, and 179 of the amino acid sequence of SEQ ID NO: 2, respectively, relative to the amino acid sequence of the polypeptide having glycine-glycine bond decomposition activity, and having glycine-glycine bond decomposition activity; A polypeptide having glycine-glycine bond decomposition activity.

2. A polynucleotide encoding the polypeptide of claim 1.

3. A vector or DNA fragment comprising the polynucleotide of claim 2.

4. A transformant containing the vector or DNA fragment described in claim 3.

5. The transformant according to claim 4, which is a microorganism.

6. An antibacterial agent comprising the polypeptide according to claim 1 as an active ingredient.

7. The antibacterial agent according to claim 6, which is an antibacterial agent against gram-positive bacteria.

8. 13. An antibacterial method using the polypeptide according to claim 1 (excluding medical treatment for humans).

Images